We also examined whether tapinarof, a potent AHR activator [44] that is utilized clinically in the treatment of psoriasis and atopic dermatitis [45,46], has the same effect as Glyteer on IL-4-induced upregulation of IL-33 expression. The gene discussed is IL33; the disease is psoriasis.